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Abstract
Background: In recent years clinical evidence has emphasized the importance of the mtDNA genetic background that hosts
a primary pathogenic mutation in the clinical expression of mitochondrial disorders, but little experimental confirmation has
been provided. We have analyzed the pathogenic role of a novel homoplasmic mutation (m.15533 A.G) in the cytochrome
b (MT-CYB) gene in a patient presenting with lactic acidosis, seizures, mild mental delay, and behaviour abnormalities.
Methodology: Spectrophotometric analyses of the respiratory chain enzyme activities were performed in different tissues,
the whole muscle mitochondrial DNA of the patient was sequenced, and the novel mutation was confirmed by PCR-RFLP.
Transmitochondrial cybrids were constructed to confirm the pathogenicity of the mutation, and assembly/stability studies
were carried out in fibroblasts and cybrids by means of mitochondrial translation inhibition in combination with blue native
gel electrophoresis.
Principal Findings: Biochemical analyses revealed a decrease in respiratory chain complex III activity in patient’s skeletal
muscle, and a combined enzyme defect of complexes III and IV in fibroblasts. Mutant transmitochondrial cybrids restored
normal enzyme activities and steady-state protein levels, the mutation was mildly conserved along evolution, and the
proband’s mother and maternal aunt, both clinically unaffected, also harboured the homoplasmic mutation. These data
suggested a nuclear genetic origin of the disease. However, by forcing the de novo functioning of the OXPHOS system, a
severe delay in the biogenesis of the respiratory chain complexes was observed in the mutants, which demonstrated a
direct functional effect of the mitochondrial genetic background.
Conclusions: Our results point to possible pitfalls in the detection of pathogenic mitochondrial mutations, and highlight the
role of the genetic mtDNA background in the development of mitochondrial disorders.
Citation: Gil Borlado MC, Moreno Lastres D, Gonzalez Hoyuela M, Moran M, Blazquez A, et al. (2010) Impact of the Mitochondrial Genetic Background in Complex
III Deficiency. PLoS ONE 5(9): e12801. doi:10.1371/journal.pone.0012801
Editor: Alejandro Lucia, Universidad Europea de Madrid, Spain
Received May 19, 2010; Accepted August 20, 2010; Published September 17, 2010
Copyright:  2010 Gil Borlado et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was partially supported by Fundacion de Investigacion Biomedica del Hospital Universitario 12 de Octubre/Agencia Pedro Lain Entralgo, and
Instituto de Salud Carlos III (ISCIII) to C.U. (grant numbers PI05-0379 and PI08-0021), and to M.A.M. (PI09-01359). T.G. was supported by grants from the ISCIII (PI06-
0213) and the Spanish Ministry of Science (MICINN) (BFU2009-09168). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cugalde@h12o.es
. These authors contributed equally to this work.
Introduction
Mitochondrial complex III (CIII, ubiquinol-cytochrome c
reductase or cytochrome bc1 complex, E.C.1.10.2.2) is a multi-
protein enzyme complex that catalyzes the transfer of electrons
from reduced coenzyme Q to cytochrome c, with a concomitant
translocation of protons across the inner mitochondrial membrane
[1]. The purified bovine complex is a symmetric homodimer with
a combined molecular mass of ,450 kDa [2,3]. Each monomer is
composed of 11 subunits, of which ten are encoded in the nucleus
and one (cytochrome b) in the mitochondrial genome. Respiratory
chain complex III deficiency [MIM 124000] is a relatively rare
cause of mitochondrial dysfunction. Mitochondrial DNA
(mtDNA) mutations in the cytochrome b (MT-CYB) gene consti-
tute a major cause of complex III deficiency, and underlie a wide
range of neuromuscular disorders [4]. These include mitochon-
drial encephalomyopathy [5], hypertrophic or histiocytoid cardio-
myopathy [6,7], or sporadic mitochondrial myopathy, where
exercise intolerance is the predominant symptom [8]. Additional
features include blood acidosis, muscle weakness or myoglobin-
uria. Defects in MT-CYB are also documented in patients with
multisystem disorders in cases of exercise intolerance accompanied
by deafness, mental retardation, retinitis pigmentosa, cataract,
growth retardation, and epilepsy [9,10]. Mutations in MT-CYB
have also been associated with Leber hereditary optic neuropathy
(LHON) [MIM: 535000], a maternally inherited disease resulting
in acute or subacute loss of central vision due to optic nerve
degeneration [11].
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with a mitochondrial defect, a strict association between the
mutation and the cellular dysfunction must be established before
assuming pathogenicity. Although many mutations in mitochon-
drial tRNA genes and coding regions have been shown to cause
diseases, the high rate of evolution of mtDNA creates many new
polymorphic sites. For this reason, a number of useful criteria have
been proposed in order to avoid the mistake of incorrect
assignment of pathogenicity to a mutation [12]. These criteria
generally include the following aspects: i) the mutation should be
preferably found in heteroplasmic state; ii) there should be a strong
association between heteroplasmic levels, clinical symptoms,
biochemical data, and family history; iii) the mutation should be
highly conserved among species; and iv) transmitochondrial
cybrids should not restore the cellular and biochemical defects in
mitochondrial function found in the original tissue; when a
defective mitochondrial function is maintained in cybrid cells
bearing mutated mtDNA, it is generally assumed that the
mutation is likely to be a pathogenic cause of disease. Additionally,
in recent years a number of studies emphasize the importance of
the mtDNA genetic background that hosts a primary pathogenic
mutation in the clinical expression of mitochondrial disorders. The
clearest example is the preferential association of the Eurasian
haplogroup J with the 11778/ND4 and 14484/ND6 LHON
pathogenic mutations [13].
In this work we report a complex III-deficient patient with early-
onset metabolic acidosis and seizures, who harboured a novel
m.15533 A.G homoplasmic mutation in the MT-CYB gene.
Although this genetic variant did not easily fulfil the pathogenicity
criteria for mtDNA mutations, by forcing the de novo functioning of
the OXPHOS system inmutanttransmitochondrial cybrids we have
demonstrated a direct functional effect of the mtDNA genetic
backgroundonthebiogenesisofthemitochondrialrespiratorychain.
Materials and Methods
Ethics Statement
This study was approved by the institutional ethics committee
(Hospital Universitario 12 de Octubre, Madrid, Spain), and was in
accordance with the Declaration of Helsinki for Human Research.
The patient’s mother has given written informed consent (as
outlined in the PLoS consent form) to publication of the case
details.
Case Report
The proband was a male born to non-consanguineous parents,
delivered at full term by caesarean after an uneventful pregnancy.
At age 23 days he presented with abnormal movements of his
arms, and generalized hypertonia. He also showed central cyanosis
with episodes of apnea that required intubation and mechanical
ventilation for twelve days, and a convulsive status with tonic-
clonic seizures, which were recurrent during the following two
days. After treatment with antiepileptic drugs, the paroxysmal
movements finally remitted. Brain computerized tomography
scans and brain ultrasonography revealed no abnormalities.
Laboratory examinations revealed persistent metabolic acidosis
that was treated with bicarbonate, elevated anion gap, and
moderate increase of resting plasma lactate (3.4 mmol/L; normal
,2). At age two years a muscle biopsy was taken, which showed a
single mitochondrial respiratory chain complex III defect. Other
studies discarded pyruvate decarboxylase deficiency and organic
acidemia. At three years of age brain magnetic resonance imaging
(MRI) displayed small abnormal signals in both thalami, and
diffuse hypersignals in T2-weighted sequence in the white matter
of the peripheral area of atrium as a consequence of myelination
delay. At the age of six he presented with developmental delay
affecting his speech skills, which started to be treated by language
therapy. He also developed behaviour disturbances and a
functional clubfoot. Brain MRI and MR spectroscopy were
normal. At present, at age nine years, he has a mild mental and
developmental delay, functional clubfoot, cognitive abnormalities,
attention difficulties and hyperactivity, initiating treatment with
methylphenidate. His parents and a maternal aunt were all
asymptomatic. His mother suffered a previous miscarriage at two
months of gestation. A maternal aunt was referred to die at two
months of age from an unknown disease.
Cell Cultures
Fibroblasts were obtained from skin biopsies and cultured in
DMEM medium (Life Technologies) supplemented with 10%
foetal calf serum (FCS) and 100 IU/ml penicillin and 100 IU/ml
streptomycin. Transmitochondrial cybrids were obtained by fusion
of 143B206 TK
- rho zero cells with control or patient-derived
enucleated fibroblasts or platelets as previously described [14]. To
block mitochondrial translation, 15 mg/ml doxycycline were
added to the culture medium. Cells were grown in exponential
conditions and harvested at the indicated time points.
Enzyme activities of mitochondrial respiratory chain
complexes
Mitochondrial respiratory chain enzyme activities were mea-
sured in muscle (quadriceps muscle biopsy), skin fibroblasts, and
cybrids as described before [15], and expressed relative to the
citrate synthase activity in muscle, and as their specific activities in
fibroblasts and cybrids (Table 1).
Genetic analyses
Total DNA was extracted from blood, muscle, fibroblasts and
cybrids by standard methods. The whole mitochondrial DNA
(mtDNA) from patient’s muscle was sequenced by SECUGEN S.L.
(Madrid, Spain). The complete mtDNA was amplified from total
DNA in 24 overlapping 800–1,000 bp-long polymerase chain
reaction (PCR) fragments. The PCR fragments were sequenced in
both strands in an ABI 3730 sequencer using a BigDye v3.1
sequencing kit (Applied Biosystems, Foster City, CA), and were
compared with the revised Cambridge reference sequence, CRS [16]
(Table 2). Discrepancies were analyzed in the human mitochondrial
genome databases MITOMAP (www.mitomap.org), mtDB (www.
genpat.uu.se/mtDB/), and GiiB-JST mtSNP (http://mtsnp.tmig.or.
jp/mtsnp/index_e.shtml). To quantify the heteroplasmy levels of the
m.15533 A.G mutation, PCR-restriction fragment length polymor-
phism (RFLP) analysis was performed in the proband’s family using
the following primers: 59-CACTATTCTCACCAGACCTC-39,
(forward) and 59-ACGCCTCCTAGTTTGTTAGG-39 (reverse),
and digestion with the restriction enzyme DdeI (New England Biolabs).
Two hundred healthy control subjects of Spanish background
obtained from the Blood Bank of our Institution were screened to
rule out the presence of mutations in the healthy population.
Additionally, sequencing ruled out mutations in the coding
regions of the following complex III nuclear genes: CYC1,
UQCRFS1, UQCRQ, UQCRH, UCRC, and BCS1L.
Bioinformatic analyses
Cytochrome b protein sequences from diverse vertebrate species
were downloaded from Uniprot (The Uniprot Consortium,
2010)[17][17], and aligned with MUSCLE v3.2 [18]. The
potential effect of the N263D and N260D mutations was evaluated
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structure of bovine complex III stored in PDB (1NTM) as a
template. Modelling was performed at the Swiss model server [19].
3D models were visualized using Chimera [20].
Quantification of the mtDNA copy number
Relative quantification of mtDNA versus nuclear DNA (nDNA)
was performed by real-time PCR in a HT 7500 Real Time PCR
System (Applied Biosystems, Foster City, CA, USA) as previously
described [21], except that the forward primer used for mtDNA
amplification was: 59-CCA CGG GAA ACA GCA GTG AT-39.
Results were presented as mean 6SD values.
Mitochondrial Protein Isolation and Blue Native Analysis
Blue native methods were performed as previously described
[21]. Primary antibodies (Molecular Probes) were raised against
the complex I NDUFS3 and NDUFA9 subunits, complex III
core2 protein, complex IV COX2 and COX5A subunits, and
complex II SDHA subunit. Peroxidase-conjugated anti-mouse IgG
was used as secondary antibody (Molecular Probes). The signal
was detected with ECLH plus (Amersham Biosciences).
Results
Genetic and biochemical analyses of the MT-CYB
m.15533A.G mutation
Mitochondrial respiratory chain enzyme activities showed a
single complex III defect in the patient’s skeletal muscle (52% of
the lowest control value), and a combined deficiency of complexes
III and IV in fibroblasts (52% and 31% of the lowest control
values respectively) (Table 1). Sequencing of the entire mitochon-
drial genome in patient’s muscle enabled easy identification of
haplogroup-specific polymorphisms and novel private substitutions
(Table 2), and confirmed that the patient belonged to the
European haplogroup H2 (GenBank sequence accession number
HM046248). Comparison of the sequence with the revised
Cambridge reference sequence (rCRS) revealed 12 synonymous
substitutions, 5 non-synonymous substitutions, and 19 substitutions
either in mitochondrial rRNAs, tRNAs or in the mtDNA D-loop
region. One missense mutation in MT-CYB (m.15533A.G) was
not previously reported in the mtDNA sequence databases, and it
was not detected in 200 ethnically-matched controls (Figure 1A).
The relative mutant load for this new nucleotide variant was
measured by PCR-RFLP analysis in blood (not shown), muscle
and fibroblasts of the patient (Figure 1B), and showed homo-
plasmic levels of the mutation in all tissues. DdeI-RFLP analysis
also showed that the MT-CYB mutation was homoplasmic in
blood from the proband’s mother and maternal aunt, both
clinically unaffected (not shown).
To discriminate between a nuclear or mitochondrial origin of
the disease, transmitochondrial cybrids were constructed by
transferring mitochondria from patient’s fibroblasts into
143B206 TK
- rho zero (ru) cells, which lack mtDNA. Ten
independent cybrid clones retained homoplasmic loads of the
m.15533A.G mutation (Figure 1B). The enzyme activities of all
respiratory chain complexes were normal in six independent
Table 2. Haplogroup affiliation and non-synonymous nucleotide changes of the mtDNA sequence from the index patient.
Genbank ID HAPLOGROUP
Non-synonymous polymorphisms
relative to rCRS
a Amino acid Change
HM046248 H2 A8860G (ATP6)T h r .Ala
G9477A (CO3)V a l .Ile
C14766T (CYB)T h r .Ile
A15326G (CYB)T h r .Ala
A15533G (CYB)A s n .Asp
arCRS refers to the revised Cambridge reference sequence [16], which belongs to haplogroup H2a.
doi:10.1371/journal.pone.0012801.t002
Table 1. Residual enzyme activities of mitochondrial respiratory chain complexes in different tissues from the index patient.
Muscle* Fibroblasts** Cybrids**
Patient
Control Range
(n=100) Patient
Control Range
(n=9)
Mutants Mean
(n=6)
Control Range
(n=5)
CI 17,1 10–30 35,1 26–50 10 4–17
CII 16,3 4,5–17,4 10 10–17 12 11–27
CI+CIII 14,5 8.5–26 122 223–750 37 32–96
CII+CIII nd - 2,7 4,4–18,5 2,8 2,6–7,3
CIII 14,6 28–98 15,1 29–87 74 13–71
CIV 22,7 16–80 15,2 49–128 39 20–36
CS 194 78–250 61 60–160 142 108–175
Enzyme activities are expressed as
*cU/U citrate synthase (CS) and
**nmol.min
21.mg prot
21. CS activity is expressed as mU/mg protein. Abnormal values are indicated in bold. nd, not determined. Complex I, CI; Complex II, CII; Complex
III, CIII; Complex IV, CIV.
doi:10.1371/journal.pone.0012801.t001
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12801Figure 1. Genetic and structural analysis of the m.15533A.G mutation. (A) Electropherogram showing the nucleotide change in patient’s
muscle DNA, indicated by arrowheads. (B) PCR-RFLP analysis of the MT-CYB mutation. Uncut (wild-type) DNA consists of a 150 bp PCR product. The
mutated sequence contains one DdeI restriction site that results in two products of 90 and 60 bp after digestion. The control sequence contains one
MseI restriction site that results in the same two products after digestion. C, wild-type control; F, proband’s fibroblasts DNA; M, proband’s muscle
DNA; Cy, control cybrid; 1, 2 and 3 refer to three independent mutant cybrid clones. (C) Alignment of cytochrome b amino acid sequences from
selected species. Asparagine at amino acid position 263 is indicated with an arrow. (D) Partial 3D-images of the cytochrome b protein. The left panel
shows the interaction site between the asparagine 263 (indicated in red) of cytochrome b and the aspartate 2 of the cytochrome c1 subunit (coloured
in green). This is the closest negatively charged side-chain of cytochrome c1, which is facing the same aqueous pocket at a distance of 11.25
Armstrongs. Asparagine at position 260 of cytochrome b is indicated in blue. The central panel shows the 3D-structure of the asparagine 263 (in blue)
in controls. The right panel shows the predicted structural effect of the N263D substitution (in red) in the patient. The images were obtained using
the Chimera software [20].
doi:10.1371/journal.pone.0012801.g001
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main genetic defect should be located in the nuclear genome.
Features of the MT-CYB m.15533A.G mutation
The m.15533A.G transition changes an asparagine into
aspartate at amino acid residue 263, within an amino acid stretch
relatively conserved amongst mammals, but not further on in
evolution (Figure 1C). Based on its crystal structure [2,3], the
cytochrome b subunit consists of eight intramembrane spanning
domains (helixes A–H). Asn 263 is located between the E–F
transmembrane helixes, within the second half of loop ef of
cytochrome b, in close contact with functional domains of the
RISP and cytochrome c1 subunits. The N263D amino acid
substitution would exchange a positive for a negative charge within
this region, possibly affecting the interaction between cytochrome
b and the RISP and cytochrome c1 subunits (Figure 1D). These
findings suggested that the N263D mutation could have an effect
on the structural integrity of mitochondrial respiratory chain
complex III. However, a structural analysis of the N263D
substitution only predicted a mild effect on the interaction
between complex III subunits. As shown in Figure 1D, residue
263 (shown as red or yellow residues on the pink-coloured chain) is
facing an aqueous pocket, and the distances to the closest residues
of cytochrome c1 (coloured in green) are larger than 7 Armstrongs.
Several other charged residues, an arginine and three aspartates,
are present at close distances, suggesting that the relative charge
introduced by the mutation is not large. A similar asparagine to
aspartate substitution at amino acid position 260 of cytochrome b
(shown in blue in the figure) was previously reported as a
polymorphism [22]. The side chain of this residue is facing the
same aqueous pocket in a very close position to that of 263.
Altogether, these data do not plead in favour to consider the
N263D as a true pathogenic mutation.
Normal steady-state levels of respiratory chain
complexes in MT-CYB mutant cells
To analyze the respiratory chain content in digitonin-extracted
mitochondria from patient’s fibroblasts and cybrids, 1D-BN-
PAGE analysis was combined with complex I in-gel activity assay
and western blot with antibodies raised against specific OXPHOS
subunits (Figure 2). In patient’s fibroblasts low steady-state levels of
respiratory chain complexes III and IV were observed, suggesting
an impaired assembly/stability defect. Consequently, decreased
enzyme activities of these complexes were found in this tissue
(Table 1). As expected from their restored enzyme activities, the
mutant cybrids displayed normal steady-state levels of respiratory
chain complexes relative to the controls.
Delayed assembly kinetics of respiratory chain complexes
in mutant cybrids
Next, we reversibly blocked for 6 days mitochondrial protein
translation with doxycycline, thus depleting the cells of OXPHOS
complexes that contained mitochondrial-encoded subunits [23].
After the release of drug inhibition, mitochondrial translation
resumed and the assembly of newly-synthesized mitochondrial
complexes was investigated by collecting cells at different time
points (0, 6, 15, 24, 48, 72, and 96 hours). Digitonin-isolated
mitochondria were analyzed by BN-PAGE electrophoresis in
combination with in-gel activity assays (Figure 3A) or Western-blot
using antibodies against subunits from different OXPHOS
complexes (Figure 3B). The signals obtained from the Western-
blots were quantified, normalized for the expression levels of
mitochondrial complex II, expressed as a percentage of the
untreated cells (which correspond to the steady-state expression
levels), and calculated the average numerical values for the
restoration curves of the respiratory complexes in control and
mutant cybrids (Figure 3C). A significant delay in the recovery
kinetics of respiratory chain complexes I, III and IV was observed
in the two independent mutant cybrids relative to two controls of
the same haplogroup (Figure 3C).
The mtDNA copy number was calculated for control and
mutant cybrids in order to exclude the possibility that the
differences observed in the assembly kinetics of respiratory chain
complexes could be due to variations in the mtDNA content. No
significant differences were found in the mtDNA/nDNA ratio
between the controls (292635) and the mutants (289638)
belonging to haplogroup H. Taken as a whole, our results
demonstrate a functional effect of the mtDNA genetic background
of the mutant clones in the assembly kinetics of respiratory chain
complexes.
Discussion
In this work we have shown the pathogenic role of the novel
m.15533A.G genetic variant in the MT-CYB gene in a patient
with metabolic acidosis and hyperlactacidemia, seizures, mild
mental delay, behaviour disturbances and a single enzyme defect
of mitochondrial respiratory chain complex III. Based on the
current standard pathogenicity criteria for mtDNA mutations, the
mutation would have been easily excluded as potentially
deleterious. Our patient harboured the mutation in homoplasmic
state, as did his clinically unaffected mother and maternal aunt.
The mutation was not highly conserved along evolution and the
predicted structural data did not plead in favour of a deleterious
effect of the N263D substitution on the structure of cytochrome b.
Although he showed defective respiratory chain enzyme activities
and protein levels in muscle and cultured fibroblasts grown in
exponential conditions, these respiratory chain enzyme activities
and assembly defects were restored to normal in transmitochon-
drial cybrids harbouring the homoplasmic m.15533A.G muta-
tion, when these cells were grown in a favourable glucose-
Figure 2. BN-PAGE analysis of mitochondrial respiratory chain
complexes in control and mutant fibroblasts and cybrids.
Mitochondrial particles were isolated as described in Methods and
40 mg of protein were analyzed on a 5–15% BN-polyacrylamide gel for
the separation of multisubunit complexes. Western-blot analysis was
performed using antibodies against the indicated OXPHOS subunits. CI,
fully-assembled complex I. CIII2, complex III dimer. CIV, complex IV.
CIII2+IV indicates the presence of the supercomplex containing
complexes III and IV. C1 and C2, control fibroblasts. P, patient’s
fibroblasts. C, control cybrid. Two independent mutant cybrids are
indicated as #1 and #2.
doi:10.1371/journal.pone.0012801.g002
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12801Figure 3. Assembly kinetics of respiratory chain complexes in control and mutant cybrids. Two different control cybrids belonging to
haplogroup H, and two independent MT-CYB mutant clones were treated for 6 days with doxycycline (an inhibitor of mitochondrial translation), the
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mutant cybrids were forced to the de novo building up and
functioning of the OXPHOS system by treating the cells with
doxycycline, we were able to observe a drastic functional effect of
the mtDNA genetic background on the assembly kinetics of the
respiratory chain complexes.
Similar observations were previously made by our group in
cybrid cell lines bearing the three classical homoplasmic LHON
mutations [21]. These cells neither showed respiratory chain
enzyme defects nor decreased steady-state levels of OXPHOS
complexes, but displayed differentially-delayed assembly rates of
respiratory chain complexes I, III, and IV amongst mutants
belonging to different mtDNA haplogroups. Likewise, the mtDNA
genetic background was recently shown to play an important role
in modulating the bioenergetics and biochemical defects in cybrids
bearing the ATP6 NARP/MILS mutation [24]. This is in
agreement with the proposed effect on protein function of single
nucleotide polymorphisms (SNPs) that are located in the coding
region, which could affect protein stability, ligand binding,
catalysis, allosteric regulation and post-translational modifications
[25]. Basal differences in OXPHOS capacities such as mitochon-
drial transcription and replication, protein synthesis, and bioen-
ergetics have recently been demonstrated in control cybrids from
different mtDNA haplogroups [26,27]. These results reveal that
specific mtDNA polymorphisms may modify the pathogenic
potential of mtDNA mutations by affecting the overall biogenesis
and function of the OXPHOS complexes.
In our MT-CYB mutant cybrids, the m.15533A.G mutation
most likely hampers the proper assembly of respiratory chain
complex III, which would further affect the formation of complex I
[28]. In addition, the mutant clones showed, besides strong
complex I and complex III assembly defects, a severe impairment
of complex IV and supercomplex CIII2+CIV assembly rates. This
effect could be explained by the presence of two mtDNA
polymorphisms in the MT-CO3 and MT-ATP6 genes, G9477A
and A8860G respectively, plus two additional mtDNA polymor-
phic variants in the MT-CYB gene, C14766T and A15326G,
(Table 2) which could add a deleterious effect to that caused by the
m.15533A.G mutation. Our results, however, do not explain the
differences in the clinical expression of the m.15533A.G
mutation among members of the proband’s family. Although
reduced penetrance is a relatively common feature of homo-
plasmic mtDNA mutations leading to mitochondrial disorders
[29,30], it suggests the requirement of additional contributors to
the clinical manifestations of the disease. For instance, most
patients with LHON disease carry homoplasmic mtDNA
mutations. Although all offspring inherit the mutation, often only
some family members will develop the disease [30], which
emphasizes the importance of nuclear genetic, epigenetic or
environmental factors as phenotypical modulators of mitochon-
drial disorders.
In general, the mutations that have the most deleterious effect
on mitochondrial function will cause obvious clinical phenotypes.
The m.3243A.G mutation, for example, usually causes a
devastating multisystem disease and fulfils all the criteria for
pathogenicity [31]. The problems may arise when a mutation
causes disease only in the presence of an additional factor, or when
it only causes a mild clinical phenotype as it occurs in our patient.
In these cases the ‘conventional’ criteria might not be applicable,
and deeper functional tests should be performed in cybrid cell lines
that harbour the mutation of interest, including i.e. oxygen
consumption and mitochondrial protein synthesis analyses, or de
novo restoration of enzyme activities and assembly of the various
components of the oxidative phosphorylation system. In this sense
our study describes a useful mechanism to unveil potentially
deleterious mutations in patients with signs of mitochondrial
disease but apparently normal respiratory chain enzyme activities.
Besides, our results point to possible pitfalls in the detection of
pathogenic mitochondrial mutations, and highlight the potentially
important effects of the genetic mtDNA background in the
development of mitochondrial disorders, which should be taken
into account when defining the pathogenicity criteria for mtDNA
mutations.
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